<DOC>
	<DOCNO>NCT01844869</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetic safety profile omacetaxine metabolites patient relapse and/or refractory hematologic malignancy advance solid tumor follow subcutaneous ( sc ) administration .</brief_summary>
	<brief_title>An Open-Label Study Investigate Pharmacokinetics Omacetaxine Mepesuccinate</brief_title>
	<detailed_description>This Phase 1 , single-center , open-label , nonrandomized study determine pharmacokinetics ( absorption , distribution , metabolism , excretion ) omacetaxine metabolites follow sc dosage 1.25 mg/m2 adult patient relapse and/or refractory hematologic malignancy advance solid tumor . The study consist screen period 28 day , follow 7-day pharmacokinetic assessment period ( period A ) include administration single radiolabeled dose omacetaxine , open-label treatment period six 28-day cycle ( period B ) , final assessment occur approximately 28±7 day end last treatment cycle . Period B begin collection 72-hour pharmacokinetic sample period A .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<mesh_term>Harringtonines</mesh_term>
	<criteria>Written inform consent obtain . The patient least 18 year age time informed consent . The patient histologically cytologically confirm diagnosis follow : Relapsed refractory leukemia , include Philadelphia chromosomepositive ( Ph+ ) , chronic myelogenous leukemia ( CML ) , acute promyelocytic leukemia ( APL ) , acute myelogenous leukemia ( AML ) , myelodysplastic syndrome ( MDS ) . Advanced solid tumor ( ie , breast , lung , head/neck , colorectal , melanoma , sarcoma ) . The malignancy must consider unresponsive accept available therapy . The patient estimate life expectancy least 3 month . The patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Other criterion apply . The patient chemotherapy , radiotherapy , radioimmunotherapy , immunotherapy within 28 day prior first dose study drug recover adverse event due agent administer previously . For patient receive therapy mitomycin C , interval 42 day . The patient receive treatment hematologic/nonhematologic malignancy . The patient previous treatment omacetaxine . The patient treat hematopoietic growth factor within 14 day study entry ( patient chronic erythropoiesis stimulate agent allow ) . The patient New York Heart Association ( NYHA ) Class 3 4 heart disease , active ischemia , uncontrolled , unstable cardiac condition treatment condition indicate control despite adequate therapy , include angina pectoris , cardiac arrhythmia , hypertension , congestive heart failure . The patient experience myocardial infarction within previous 12 week . The patient solid tumor symptomatic central nervous system ( CNS ) metastases . The patient active , uncontrolled systemic infection consider opportunistic , life threatening , clinically significant time treatment . Other criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>omacetaxine</keyword>
	<keyword>omacetaxine mepesuccinate</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>